Elanco Animal Health Stock (NYSE:ELAN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.87

52W Range

$13.16 - $27.72

50D Avg

$22.88

200D Avg

$22.47

Market Cap

$12.01B

Avg Vol (3M)

$6.19M

Beta

1.70

Div Yield

-

ELAN Company Profile


Elanco Animal Health, a firm dedicated to animal well-being, creates, produces, and commercializes a diverse array of solutions for both companion animals and livestock. For household pets, the company provides preventative health solutions, including parasiticides and vaccinations, designed to guard against common ailments like worms, fleas, and ticks, with notable brands such as Seresto, Advantage, Advantix, and Advocate. Additionally, Elanco supplies therapeutic treatments for canine and feline conditions including pain, osteoarthritis, ear infections, cardiovascular issues, and dermatological problems, marketed under labels like Galliprant and Claro. Its portfolio for agricultural animals encompasses vaccines, antibiotics, parasiticides, and other essential products for poultry and aquaculture farming. This segment also features nutritional supplements such as enzymes, probiotics, and prebiotics to support animal health and growth. Furthermore, the company offers a comprehensive suite of products for ruminant and swine operations, comprising vaccines, antibiotics, implants, and parasiticides, often recognized by brands like Rumensin and Baytril. Elanco distributes its offerings through various channels, including independent distributors, veterinary clinics, and a broad spectrum of farm animal producers, from cattle and dairy farms to pig, poultry, and aquaculture enterprises. Established in 1954, Elanco Animal Health Incorporated maintains its corporate headquarters in Greenfield, Indiana.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

9,000

IPO Date

Sep 20, 2018

Website

ELAN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Contract Manufacturing$53.00M$46.00M$54.00M
Farm Animal$2.36B$2.25B$2.22B
Pet Health$2.30B$2.14B$2.14B
Poultry$858.00M$796.00M$716.00M
Swine$379.00M$366.00M$384.00M
Cattle$1.13B$1.01B$944.00M

Fiscal year ends in Dec 25 | Currency in USD

ELAN Financial Summary


Dec 25Dec 24Dec 23
Revenue$4.71B$4.44B$4.42B
Operating Income$795.00M$251.00M$326.00M
Net Income$-232.00M$338.00M$-1.23B
EBITDA$795.00M$1.49B$-224.00M
Basic EPS$-0.47$0.68$-2.50
Diluted EPS$-0.47$0.68$-2.50

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 06, 26 | 12:00 AM
Q4 25Feb 24, 26 | 12:00 AM
Q3 25Nov 05, 25 | 8:00 AM

Peer Comparison


TickerCompany
EHCEncompass Health Corporation
RVMDRevolution Medicines, Inc.
NBIXNeurocrine Biosciences, Inc.
VTRSViatris Inc.
QGENQiagen N.V.
RVTYRevvity, Inc.
RDYDr. Reddy's Laboratories Limited
ALGNAlign Technology, Inc.
SOLVSolventum Corporation
ENSGThe Ensign Group, Inc.